Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
Completed · Phase 1/Phase 2
Conditions studied: Neutropenia
In brief
Anidulafungin is a medicine being developed for treatment of adults with certain kinds of fungal infections. This study is evaluating anidulafungin in children and adolescents who have fever and a low white blood cell count (neutropenia).
Key facts
- Study ID
- NCT00056381
- Run by
- Pfizer
- People needed
- 25
- Starts
- 2003-07-01
- Expected to finish
- 2004-06-01
- Last updated by the study team
- 2008-10-21
Who can join
Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Versicor — King of Prussia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.